Medtronic PLC
NYSE:MDT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/S
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Valuation Scenarios
If EV/S returns to its 3-Year Average (3.9), the stock would be worth $90.4 (10% upside from current price).
| Scenario | EV/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 3.5 | $81.86 |
0%
|
| 3-Year Average | 3.9 | $90.4 |
+10%
|
| 5-Year Average | 4 | $92.69 |
+13%
|
| Industry Average | 4.1 | $96.21 |
+18%
|
| Country Average | 2.3 | $54.77 |
-33%
|
Forward EV/S
Today’s price vs future revenue
| Today's Enterprise Value | Revenue | Forward EV/S | ||
|---|---|---|---|---|
|
$130.2B
|
/ |
Jan 2026
$35.5B
|
= |
|
|
$130.2B
|
/ |
Apr 2026
$36.5B
|
= |
|
|
$130.2B
|
/ |
Apr 2027
$38.9B
|
= |
|
|
$130.2B
|
/ |
Apr 2028
$40.8B
|
= |
|
|
$130.2B
|
/ |
Apr 2029
$41.5B
|
= |
|
|
$130.2B
|
/ |
Apr 2030
$43.8B
|
= |
|
Forward EV/S shows whether today’s EV/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | EV/S | P/E | ||||
|---|---|---|---|---|---|---|
| IE |
|
Medtronic PLC
NYSE:MDT
|
106.4B USD | 3.5 | 22.8 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
167.2B USD | 15.8 | 57.8 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
161.2B USD | 3.6 | 25.9 | |
| US |
|
Stryker Corp
NYSE:SYK
|
125.8B USD | 5.3 | 38 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
88.9B USD | 4.6 | 24.2 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
48.5B USD | 6.9 | 43.3 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
40.1B EUR | 2 | 18.8 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
45.8B USD | 10.6 | 42.8 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
42.8B USD | 2.7 | 24.1 | |
| US |
|
Resmed Inc
NYSE:RMD
|
32.3B USD | 5.6 | 21.2 | |
| US |
|
GE Healthcare Technologies Inc
NASDAQ:GEHC
|
32.1B USD | 1.8 | 15.1 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.1 |
| Median | 2.3 |
| 70th Percentile | 4.2 |
| Max | 2 205.1 |
Other Multiples
Medtronic PLC
Glance View
In the intricate world of medical technology, Medtronic PLC stands tall as one of the foremost innovators transforming the landscape of healthcare. Founded in 1949 as a humble medical supply repair shop in Minnesota, Medtronic has grown into a global titan, driven by the enduring mission to alleviate pain, restore health, and extend life. The company's breadth is vast, touching nearly every aspect of patient care, from advanced robotic-assisted surgery systems to sophisticated insulin pumps. At its core, Medtronic thrives on relentless research and development, continually bridging the gap between cutting-edge technology and practical medical solutions. By forging deep alliances with healthcare providers and systems around the globe, the company ensures its innovations are not only groundbreaking but also widely accessible. The company's financial engine purrs to life primarily through the development and sale of medical devices across four major segments: Cardiac and Vascular Group, Minimally Invasive Therapies, Restorative Therapies Group, and Diabetes Group. Each unit meticulously focuses on innovating and providing solutions relevant to its field, ensuring a diversified portfolio with robust pipelines. For instance, within the Cardiac and Vascular Group, Medtronic supplies life-saving products like pacemakers and stents while also exploring breakthrough therapies such as transcatheter heart valves. By capitalizing on a global presence, the company strategically taps into both mature markets in North America and Europe and emerging markets across Asia and Latin America, thereby driving substantial revenue streams. Through this multifaceted operational framework, Medtronic not only sustains its market dominance but also reinvests in the future of medical technology, symbolizing a perpetual cycle of growth and innovation.